Make sure you follow our Twitter feed and subscribe to our LinkedIn webpage!
Last week we announced the TGA approval for Cell Therapies to manufacture Novartis’ CAR-T therapy, Kymriah® (tisagenlecleucel) in Melbourne, Australia. Take a behind-the-scenes look into the hard work and collaboration [...]
Cell Therapies Pty Ltd, a contract manufacturing organisation located within the Peter MacCallum Cancer Centre, Melbourne, has become the first approved local CAR-T commercial manufacturing site for Kymriah® Kymriah® (tisagenlecleucel), [...]
The Board of Cell Therapies Pty Ltd (CTPL) has announced that Dr Dawn Driscoll will be stepping down from her post as CEO, effective 31 Dec 2020. A. Prof. Leslie [...]
Cell tracking case study “Better diagnostic technologies for cancer detection” has been published on the AusIndustry website. [...]
Cell Therapies Pty Ltd and Peter MacCallum Cancer Centre, in collaboration with RMIT University, the Royal Children’s Hospital, and Cyclotek (Aust) Pty Ltd, is pleased to present the “First in [...]
While hospitals in many parts of the world have faced unprecedented challenges with routine clinical services and had to suspend clinical trials, hospitals in Australia have not been as adversely [...]
Health Minister Greg Hunt announces funding for Kymriah today at the Peter MacCallum Cancer Institute Cell Therapies Pty Ltd (CTPL), a recognised leader in the development, manufacturing and distribution of [...]
Cell Therapies Pty Ltd will be attending the Phacilitate Leaders World Conference, part of Advanced Therapies Week, in Miami from 21-24 January 2020. Nathan Smith, our Project Portfolio Manager responsible [...]
Cell Therapies Pty Ltd will be attending the International Society for Cell & Gene Therapy (ISCT) Annual Meeting in Paris from 27-30 May 2020. We will be sponsoring the Global [...]
For the first time in Australia, Cell Therapies Pty Ltd (CTPL), a recognised leader in the manufacturing and distribution of cell-based therapies, has been granted a product class (T-cells) GMP manufacturing [...]
Cell Therapies Pty Ltd hosted a very unique breakfast session at ISCT on Thursday 30th May. Our own Nathan Smith chaired this event, which gave a deep look into clinical [...]
Cell Therapies Pty Ltd will be holding an Open House on Tuesday, 28 May 2019 at 17:30 in conjunction with the 2019 International Society for Cell and Gene Therapy (ISCT) [...]
[...]
(19 Dec 18) Novartis Australia has announced the TGA approval of Kymriah® (tisagenlecleucel), for the treatment of two types of aggressive cancers. This one-time treatment is called “CAR-T” cellular therapy, [...]
Cell Therapies Pty Ltd is delighted to announce the appointment of Dr Dawn Driscoll as its new Chief Executive Officer. Dawn is highly experienced in the cellular therapy industry and [...]
Melbourne, Australia 26 June 2017: Cell Therapies has been awarded $1,000,000 in funding by the Australian Government Department of Industry, Innovation and Science through the Global Innovation Linkages programme. On [...]
Melbourne, Australia 20 February 2017: Cell Therapies commitment to, and excellence in, bringing innovative cellular therapies into clinical practise has been recognised with an IMAPAC Asia-Pacific Bioprocessing Excellence Award. Managing [...]
Melbourne, Australia, 11 October 2016: Cell Therapies Pty Ltd (CTPL) is pleased to announce that CEO and Managing Director Dr Tim Oldham has been elected to the Board of the [...]
CT’s contribution to ISCT 2016 Representatives from Cell Therapies presented at ISCT Singapore on the following topics: Apheresis – Douglas Watson, Cell Therapy Specialist Initial Comparison of 3 apheresis platforms [...]
Melbourne 8 Feb 2016: Cell collection via apheresis is the starting point for manufacture of many cellular therapies, including most immuno-therapies. The high patient-to-patient variability, coupled with the specialised skills [...]
REFORM NEEDED TO FULFILL OUR BIOTECH POTENTIAL is an article by AusBiotech’s Chief Executive, Dr Anna Lavelle, published in Melbourne’s Herald Sun on the 25 September 2015. Dr Lavelle’s article [...]
Melbourne and Kuala Lumpur 30 Sep 2015: Cell Therapies Pty Ltd (CTPL) has today received official notification from the Malaysian Government and Malaysian Biotechnology Corporation (BiotechCorp) that its Malaysian subsidiary, Cell Therapies [...]
Cell Therapies’ Chief Scientific Officer, Dr Dominic Wall will participate in AusBiotech2015 as part of the Regenerative Medicine Forum. He is quoted today in an article by Sue Dunlevy highlighting [...]
Cell Therapies Pty Ltd has been profiled in Australian Biotechnology’s most recent edition featuring advanced manufacturing. As cellular therapies transform healthcare for many unmet medical needs, new manufacturing capacity with [...]
Nagoya, Japan and Melbourne, Australia: 28 April 2015: PharmaBio Ltd and Cell Therapies Pty Ltd announce that they have entered a memorandum of understanding to establish an alliance that will [...]
Cell Therapies Pty Ltd (Cell Therapies), a leading manufacturer and distributor of cellular therapies in the Asia-Pacific region, is pleased to announce significant change to board structure in anticipation of [...]
Melbourne, Australia 21 April 2014: Cell Therapies Pty Ltd (Cell Therapies), the leading manufacturer and distributor of cellular therapies in Asia Pacific, has appointed Dr Tim Oldham as CEO to [...]
Cell Therapies Pty Ltd is an essential partner in a new $60 million Commonwealth Government project designed to help translate promising cellular therapy treatments from the lab [...]
Cell Therapies P/L has become an essential partner in the recently approved Cooperative Research Center for Cell Therapies Manufacturing (CRC-CTM). The combination of world leading academic researchers with local and [...]
Cell Therapies Pty Ltd is pleased to announce that Dr Christian Behrenbruch has been appointed as Chairman of the Melbourne-based life sciences company. Dr Behrenbruch will also serve as a [...]
Cell Therapies has announced an exclusive licensing agreement with South Korean-based Medipost for the distribution and manufacture of its innovative product Cartistem® a cellular treatment for osteoarthritis (OA) and focal [...]
